Single daily dose amikacin in paediatric patients with severe Gram-negative infections

Hugo Trujillo, Jaime Robledo, Carlos Robledo, David Andrés Espinal, Galo Garces, J. Mejia, Carlos Andrés Restrepo, Fabiola de Restrepo, G. I. M. de Rodriguez, MJ Guitierrez

Journal of Antimicrobial Chemotherapy · 1991 · 20 citations · 0 references

Concepts

Abstract

Twenty-five children with serious Gram-negative infections were treated in a prospective study with amikacin 20 mg/kg administered in a single daily dose as a 30 min iv infusion for 4 to 12 days. In nine cases the amikacin was combined with beta-lactam antibiotics. Escherichia coli were the most frequent bacteria isolated followed by K. pneumoniae, Providencia and Enterobacter spp. and Pseudomonas aeruginosa with MICs ranging from 1 to 16 mg/l. Mean (+/- S.D.) peak and trough concentrations of days 1 and 4 of therapy ranged from 49 +/- 13.5 to 53.6 +/- 13.4 mg/l and 6 + 1.4 to 7.7 +/- 4.1 mg/l respectively. All patients were clinically and bacteriologically cured. No significant adverse reactions were observed. The results suggest that administration of a single daily dose of 20 mg/kg amikacin should be considered practical and safe in children. Further studies are needed.